EMA guideline suggests for typical AD, the most common form of dementia, the CSF measurements (decreased Aβ1–42 together with increased total tau or p-tau) following in-vivo evidence of the pathology (increased tracer retention on Aβ-PET) [32]. This evidence concerns the gene MAPT and Alzheimer disease.